Project Grant R01CA289576
Award Date
12/5/24
Completion Date
11/30/29
Dollars Obligated
$567K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to validate a novel preclinical mouse model of lung squamous cell carcinoma (SCC) premalignancy and use it to screen and test prevention agents. The $602,315 award to the University of Colorado-Denver will: Define the human relevance of the in vivo NTCU/cigarette smoke mouse model of lung SCC premalignant lesions. Validate an ex vivo precision cut lung slice...
This Project Grant award of $631,156 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover the core mechanisms driving lineage plasticity (LP) in EGFR-mutant lung adenocarcinoma (LUAD). The research aims to systematically define the epigenetic, transcriptional, and signaling alterations that facilitate the transformation of LUAD to the more aggressive small cell lung cancer (SCLC) subtype, a lethal mechanism...
This Project Grant award of $352,275.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop a novel agent called MITOMET to target mitochondria in lung cancer cells with co-occurring KRAS and LKB1 mutations. The 5-year project, which began on January 1, 2025, seeks to assess the safety and efficacy of MITOMET in suppressing the malignant progression of lung tumors, determine its ability to modulate the tumor immune microenvironment, and...
This $627,833 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) aims to develop an informatics platform that integrates molecular and pathological data from various lung cancer preclinical models and patient tumors. The goal is to assess the fidelity of these preclinical models through comparative analyses. The University of Texas Southwestern Medical Center, the prime awardee, will work with Duke University as a sub-awardee to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $160,330 to the University of Illinois to develop novel lung adenocarcinoma models that better capture the initiation, progression, and composition of primary human lung tumors. The researchers aim to introduce oncogenic mutations into primary human lung stem and progenitor cells, and then culture them as tumor organoids or xenograft them into immunodeficient mice. This work seeks to...
This $680,507 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to elucidate the landscape of druggable targets for eliminating cancer persister cells in KRAS-mutant non-small cell lung cancer. The 5-year project, awarded to The Regents of the University of California, San Francisco, will: (1) illuminate signals that promote persistence in physiological contexts; (2) identify and validate targets that inhibit persistence; and (3)...
The University of Colorado-Denver was awarded a $375,134 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to investigate a novel approach for reducing off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize the innate immune response that can tighten epithelial barriers and limit nanoparticle deposition in healthy tissues, and to leverage this response to enhance delivery of chemotherapeutic agents to tumors...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will provide $368,288 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research aimed at understanding molecular mechanisms contributing to disparate lung cancer outcomes experienced by patients of African ancestry. The research project will: 1) Determine how EGFR signaling differs based on patient genetic ancestry, 2) Quantify the interplay...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $158,365 to the University of North Carolina at Chapel Hill to study the effects of NRF2 signaling on the development of lung squamous cell carcinoma (LUSC). The research aims to understand how NRF2 activation impacts LUSC initiation, progression, and the tumor microenvironment using a novel genetically-engineered mouse model. The University of Washington will perform multi-omics...